LBA8_PR - KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Peter Schmid ,Y.H Park,Fátima Cardoso ,Carsten Denkert ,Mamiko Takahashi ,Lajos Pusztai ,Sherko Küemmel ,Jing Zhao ,Jonas Bergh ,Liyi Jia ,Theodoros Foukakis ,Nadia Harbeck ,Gursel Aktan ,Peter A Fasching ,Rina Hui ,Heather L Mcarthur ,Javier Cortés ,Rebecca Dent ,Vassiliki Karantza ,Joyce O’shaughnessy

doi:10.1093/annonc/mdz394.003

LBA8_PR - KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Peter Schmid , Y.H Park + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdz394.003

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 50	License type: elsevier-specific: oa user license

#Research Grant #Expert Testimony + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA8_PR - KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Full Text